Search
Research
Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179OLIG2-expressing tumor stem cells have been shown to drive recurrence in Sonic Hedgehog (SHH)-subgroup medulloblastoma (MB) and patients urgently need specific therapies to target this tumor cell population.
Research
Brain TumourBrain tumours are the second most common cancer in children (after leukaemia).
Research
Propofol, Anesthesia, and Neurocognitive Outcomes in Patients with Pediatric Leukemia: Are We Missing the Forest for the Trees?Britta Regli-von Ungern-Sternberg AM FAHMS MD, PhD, DEAA, FANZA Chair of Paediatric anaesthesia, University of Western Australia; Consultant
Research
Confirmation of childhood acute lymphoblastic leukemia Variants, ARID5B and IKZF1, and interaction with parental environmental exposuresThe polygenic nature of childhood ALL predisposition together with the timing of environmental triggers may hold vital clues for disease etiology.
News & Events
Study finds folate protects against childhood brain tumoursA national study led by Perth's Telethon Institute has found that folic acid supplements before and during pregnancy reduces the risk of childhood brain tumours
News & Events
New insight into treatment options for rare childhood brain tumour, 2011 Media Release, Telethon Institute for Child Health ResearchA new study led by Australian researchers has outlined for the first time the best treatment options for children suffering from meningioma
News & Events
Continuing the cancer fightWork by the Institute's Division of Children's Leukaemia and Cancer Research has been recognised with three research grants from the Cancer Council of WA.
News & Events
Apache Energy joins Telethon Institute in cancer research partnershipApache Energy and the Telethon Institute for Child Health Research today signed a two-year partnership
News & Events
New study examines vacccine to prevent cervical cancerThe Telethon Institute for Child Health Research today announced a new study investigating a vaccine to prevent infection of Human Papilloma Virus (HPV).
Research
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemiaOur study provides evidence that OT-82 is a promising new therapeutic strategy for a broad spectrum of high-risk pediatric acute lymphoblastic leukemia